logo

For the Inventor, By the Inventor

Kobe, Japan

Yoshio Ueda

This inventor holds 8 USPTO granted patents. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1986-1991.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshio Ueda. Retrieved from https://idiyas.com/inventor/yoshio-ueda-5exk0h4b

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 100.0

Average Co-Inventor Count = 4.6

ph-index = 7

Forward Citations = 443(Granted Patents)


Location History:

  • Mikagenakamachi, JP (1986)
  • Koube, JP (1987)
  • Mikagenaka, JP (1988)
  • Kobe, JP (1988 - 1991)

Company Filing History:

goldMedal8 out of 940 
 
Fujisawa Pharmaceutical Company, Ltd.
 patents

Years Active: 1986-1991

Loading Chart...
8 patents (USPTO):Explore Patents
1. 5045553 - Pharmaceutical composition for percutaneous drug absorption and (1991-09-03),
2. 4916138 - Solid dispersion composition of FR-900506 substance (1990-04-10),
3. 4889721 - Sustained-release percutaneous preparations (1989-12-26),
4. 4871549 - Time-controlled explosion systems and processes for preparing the same (1989-10-03),
5. 4781115 - Tablet printing machine with roll cleaning system (1988-11-01),
6. 4749574 - Sustained-release transdermal delivery preparations (1988-06-07),
7. 4690822 - Novel drug carrier and pharmaceutical preparation comprising the same (1987-09-01),
8. 4575548 - Occlusion compound of 2-nitroxymethyl-6-chloropyridine with (1986-03-11),

Title: Innovator Yoshio Ueda: Pioneering Pharmaceutical Advancements from Kobe, JP

Introduction

Yoshio Ueda, an accomplished inventor based in Kobe, Japan, has made significant contributions to the field of pharmaceuticals. With an impressive portfolio of eight patents, Ueda's work has focused on advancing drug absorption methods, ultimately improving patient care through innovative solutions.

Latest Patents

Ueda's latest patents showcase his dedication to enhancing drug delivery systems. One notable patent is for a pharmaceutical composition designed for percutaneous drug absorption. This formulation comprises 5-isopropyl 3-methyl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, combined with ethanol and/or an unsaturated higher fatty acid. This invention is capable of promoting the effective absorption of the active compound through the skin.

Another recent patent involves a solid dispersion composition of the FR-900506 substance. This innovative formulation combines the FR-900506 substance with water-soluble hydroxypropyl methylcellulose, allowing for better dispersion. The composition operates within a specified weight ratio of the two components, showcasing Ueda's meticulous approach to pharmaceutical formulation.

Career Highlights

Yoshio Ueda is affiliated with Fujisawa Pharmaceutical Company, Ltd., where he has leveraged his expertise to drive advancements in the pharmaceutical industry. His work is characterized by a commitment to improving drug absorption techniques, resulting in more effective treatments for patients.

Collaborations

Throughout his career, Ueda has collaborated with esteemed colleagues such as Fumio Shimojo and Kazutake Kado. These partnerships have facilitated the exchange of ideas and innovation, further enhancing the quality of their collective contributions to pharmaceutical sciences.

Conclusion

Yoshio Ueda's innovative spirit and dedication to improving drug formulation are evident in his numerous patents and collaborations. His work at Fujisawa Pharmaceutical Company, Ltd. exemplifies a commitment to advancing healthcare through innovative pharmaceutical solutions. With each patent, Ueda continues to influence the industry positively, paving the way for future advancements in drug delivery and absorption methods.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…